Characterisation of burden of illness measures associated with human (Fluoro)quinolone-resistant Campylobacter spp. infections - a scoping review

Epidemiol Infect. 2022 Nov 11:150:e205. doi: 10.1017/S095026882200139X.

Abstract

Campylobacter spp. are one of the most common causes of bacterial gastroenteritis in Canada and worldwide. Fluoroquinolones are often used to treat complicated human campylobacteriosis and strains of Campylobacter spp. resistant to these drugs are emerging along the food chain. A scoping review was conducted to summarise how human (fluoro)quinolone-resistant (FQR; quinolones including fluoroquinolones) Campylobacter spp. infections are characterised in the literature by describing how burden of illness (BOI) associated with FQR is measured and reported, describing the variability in reporting of study characteristics, and providing a narrative review of literature that compare BOI measures of FQR Campylobacter spp. infections to those with susceptible infections. The review identified 26 studies that yielded many case reports, a lack of recent literature and a lack of Canadian data. Studies reported 26 different BOI measures and the most common were hospitalisation, diarrhoea, fever and duration of illness. There were mixed results as BOI measures reported in literature were inconsistently defined and there were limited comparisons between resistant and susceptible infections. This presents a challenge when attempting to assess the magnitude of the BOI due to FQR Campylobacter spp., highlighting the need for more research in this area.

Keywords: Burden of illness; Campylobacter spp.; fluoroquinolone resistance; human infections; scoping review.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Campylobacter Infections* / drug therapy
  • Campylobacter Infections* / epidemiology
  • Campylobacter Infections* / microbiology
  • Campylobacter jejuni*
  • Campylobacter*
  • Canada / epidemiology
  • Cost of Illness
  • Drug Resistance, Bacterial
  • Fluoroquinolones / pharmacology
  • Fluoroquinolones / therapeutic use
  • Humans
  • Quinolones* / pharmacology
  • Quinolones* / therapeutic use

Substances

  • Quinolones
  • Fluoroquinolones
  • Anti-Bacterial Agents